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Abstract: Choroidal melanoma is the commonest adult primary intraocular tumour,
1 and usual sites of secondary spread 
are to liver, bone and lung. Although delayed recurrence of ipsilateral orbital melanoma is well documented, metastasis to 
the contralateral orbit is a rarely encountered phenomenon. We describe a case of metastatic spread to the contralateral orbit 
in a patient 12 years after proton beam radiotherapy of choroidal melanoma.
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Case Report
A 73 year old lady attended ophthalmic outpatients in 1993 describing photopsia in her left pseudophakic 
eye. Snellen visual acuity was right eye 6/9, left eye 6/18. Dilated fundoscopy demonstrated an elevated, 
pigmented mass in the superotemporal quadrant of her left eye approximately 3 disc diameters from 
the optic nerve head. The clinical appearance was consistent with malignant melanoma of the choroid 
and ultrasound (U.S.) B scan demonstrated a lesion of 14 mm width and 7 mm height. Haematological 
markers, chest radiography and liver ultrasound were all normal. Following referral to a national centre 
for ocular oncology, a course of proton beam radiotherapy was instituted and the patient attended for 
regular follow up. Tumour dimensions were repeatedly assessed and found to be stable and regular 
clinical review until June 2005 demonstrated no change in the fundal mass, or anterior extension in 
relation to scleral markers inserted at the time of proton beam radiotherapy. No scleral extension was 
evidenced on thorough orbital ultrasound, nor was there any evidence of systemic involvement.
In July 2005, the patient now aged 85, presented with sudden, non-axial, painless proptosis of the 
right globe associated with upper lid ptosis. There was 2 mm proptosis and medial and inferior displace-
ment of 2 mm and 8 mm respectively (Fig. 1). There was associated oedema and erythema of the soft 
tissue but no signiﬁ  cant pain or heat on palpation. Orbital CT displayed a well-deﬁ  ned, non-enhancing, 
rounded mass lesion in the superolateral right orbit extending medially and inferiorly into the intraconal 
space displacing the superior rectus and optic nerve (Fig. 2). Histology of the biopsied lesion showed 
a necrotic malignant melanoma composed of epithelioid cells containing large nuclei with prominent 
nucleoli and a moderate amount of pink cytoplasm. Focally the cells contained melanin pigment. 
These expressed the melanocytic markers melan A and HMB 45 on immunohistochemistry but were 
non-reactive to S100 and CAM 5.2. (Fig. 3).
Systemic evaluation with CT scan of chest, abdomen and pelvis showed multiple metastatic 
deposits in the liver and at least one in either lung base. Referral to the regional oncology unit ensued 
and palliative chemotherapy of oral Temozolomide was commenced. Additional treatment with oral 
dexamethasone 4 mg daily greatly improved the right orbital tissue swelling and globe proptosis 
and the patient remained comfortable for 6 months. She died one year following this presentation.
Discussion
Orbital metastases most commonly originate from lung, breast, kidney and prostate malignancy, and 
account for around 2%–9% of orbital neoplasms.
1 They occur most frequently in females in the 5th–7th 6
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decade. Of melanotic lesions, cutaneous growths 
account for 5.3%–10.5% of all orbital metastases, 
versus 1.8%–2.9% for uveal primaries.
3 Choroidal 
melanoma metastasising to the contralateral orbit 
is rare.
2–5,7–9
Studies report a mean age range of patients with 
choroidal melanoma metastatic to the orbit of 
54.2–61 years old.
5,6 The time interval between 
diagnosis of the primary lesion and subsequent 
detection of orbital metastases for the majority falls 
between 6 months–10 years,
4 with an average of 
3 years.
6 At 12 years, this patient shows one of the 
longest intervals between primary diagnosis and 
subsequent contralateral orbital spread. Four reported 
cases are longer; ranging from 15 to 40 years.
4,7,8,9 
Choroidal melanoma is undoubtedly aggressive, an 
estimated 70% of patients developing metastatic 
disease within 5 years of treatment of the primary.
2
Papers often describe overt systemic spread 
preceding orbital metastases from choroidal 
melanoma.
3,6 Unusually in this patient, an orbital 
secondary lesion was the first sign of remote 
spread. Until 1994, only 5 cases had been described 
demonstrating this pattern of secondary spread.
8 
Regardless of how the disease evolves, the 
appearance of metastases heralds imminent demise, 
mean patient survival being less than one year.
6 
The propensity for orbital metastases also appears 
unrelated to the form of treatment employed for 
Figure 1. Right eye: non-axial proptosis of globe.
Figure 2. CT Scan Orbits: mass in right orbit.7
Melanoma spread to contralateral orbit
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the primary, literature review shows roughly equal 
numbers of patients having undergone enucleation 
compared to other modalities.
Although this patient was pseudophakic when 
diagnosed, preoperatively, a thorough fundal 
examination had been performed and was satisfac-
tory. Related literature is restricted to cataract 
extraction after melanoma treatment. One case 
series reported an incidence of 8.3% tumour 
metastases following cataract extraction in eyes 
with treated choroidal melanoma.
10 In the full 
cohort of 72 patients, the mean time from melanoma 
treatment to cataract surgery was 21.5 months. The 
Collaborative Ocular Melanoma Study Group 
found that cataract surgery in eyes treated with 
iodine 125 brachytherapy for choroidal melanoma 
did not adversely affect mortality or metastases.
11 
Here, the interval from treatment to cataract surgery 
was undetermined, but for patients having cataract 
extraction earlier than 5 years post melanoma treat-
ment, the time span from the report of visually 
signiﬁ  cant lens opacity to surgery was 1.5 years.
11 
We therefore would not recommend cataract 
surgery in an eye with a melanoma unless it has 
been shown to be successfully treated and stable 
for at least one year.
Although rare, contralateral orbital spread of 
choroidal melanoma is becoming an increasingly 
recognised clinical phenomenon. In contrast, 
post-mortem studies estimate that 1/3 of patients 
dying from disseminated melanoma (cutaneous 
and choroidal) have eye and orbital metastases, 
possibly due to terminal disease spread
3. In view 
of the rarity of choroidal melanoma spreading to 
the contralateral orbit, and the underlying systemic 
spread often concurrent with ocular and orbital 
metastases, we do not recommend regular screen-
ing with costly MRI scans. Standard screening for 
liver and lung metastases are at present more 
appropriate. Earlier detection of metastases may 
prolong patient survival but all previous reports 
suggest a uniformly poor prognosis for this aggres-
sive condition. This case demonstrates how sys-
temic spread may manifest many years following 
primary presentation, and can evade continued 
rigorous follow up, reinforcing the need for careful 
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Figure 3. A) Section of the orbital biopsy showing fragments of necrotic tumour. B) Pleomorphic tumour cells with prominent nucleoli. Some 
tumour cells contain melanin pigment. E) HMB45 stains the viable tumour cells while the necrotic areas are unstained. F) MELAN A stain 
within viable tumour cells.8
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patient counselling regarding prognosis of this 
unpredictable and insidious disease.
Statement of Conﬂ  ict of Interest
The authors have no conﬂ  ict of interest, ﬁ  nancial 
or otherwise in the publication of this material.
References
 1.  Shakin EP, Shields JA. The Eye and Ocular Adnexa in Systemic 
Malignancy. Cancer Metastatic to the Orbit. In Duane’s Clinical 
Ophthalmology. 1989;5(34):4.
 2.  Gupta M, Rennie IG Correspondence. Orbital metastasis from a 
choroidal melanoma. Eye. 2005;19:227–229.
  3.  Zografos L, Ducrey N, Beati D, Schalenbourg A, Spahn B, Balmer A 
et al. Metastatic Melanoma in the Eye and Orbit. Ophthalmology. 
2003;110(11):2245–2255.
 4.  Coupland SE, Sidiki S, Clark BJ, McClaren K, Kyle P, Lee WR. 
Metastatic Choroidal Melanoma to the Contralateral Orbit 40 Years 
After Enucleation. Arch Ophthalmol. 1996;114:751–756.
 5.  Drummond S, Fenton S, Pantilidis EP, Harnett AN, Kemp EG. 
Correspondence. A case of cutaneous melanoma metastatic to the right 
eye and left orbit. Eye. 2003;17:420–422.
  6.  Orcutt JC, Char DH. Melanoma Metastatic to the Orbit. Ophthalmology. 
1988;95(8):1033–1037.
  7.  Singh AD, Shields JA, Shields CL, Takami Sato. Choroidal Melanoma 
Metastatic to the Contralateral Choroid. Am J Ophthalmol. 2001;
132(6):941–943.
  8.  Bowling BS, Damato BE, Foy PM. Choroidal Melanoma Metastatic 
to the Contralateral Orbit: Implications for Patient Management. Eye. 
1994;8:144–145.
  9.  Shields JA, Perez N, Shields CL, Singh AD, Eagle RC Jr. Orbital 
Melanoma Metastatic from Contralateral Choroid: Management 
by Complete Surgical Resection. Ophthal Surg Lasers. 2002;
33(5):416–420.
10. Wachtlin J, Bechrakis NE, Schueler AO, Helbig H, Bornfeld N, 
Foerster MH. Phacoemulsiﬁ  cation following treatment of choroidal 
melanoma. Graefe’s Arch Clin Exp Ophthalmol. 2000;238:
942–948.
11.  Collaborative Ocular Melanoma Study Group. Incidence of cataract 
and outcomes of cataract surgery in the first 5 years after 
iodine 125 brachytherapy in the collaborative ocular melanoma study. 
Ophthalmology. 2007;114(7):1363–1371.